Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,104 public trials 2,042 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT02760485

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Mayo Clinic Arizona Scottsdale, Arizona, United States
  • City of Hope National Medical Center Duarte, California, United States
  • Pacific Shores Medical Group Long Beach, California, United States
  • LAC-USC Medical Center/Kenneth Norris Jr Cancer Hospital Los Angeles, California, United States
View all 21 locations
View Trial Details
Completed

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

NCT00003615

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +27 more
Locations
  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, Illinois, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • CCOP - Southern Nevada Cancer Research Foundation Las Vegas, Nevada, United States
  • Trinitas Hospital - Jersey Street Campus Elizabeth, New Jersey, United States
View Trial Details
Completed

Virtual Reality in the Management of Pain in Pediatrics: a Multi-center Randomized Clinical Trial (RealPED)

NCT05902585

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
Locations
  • Centre de Salut de Castelló Castellon, Valencia, Spain
  • Centre de Salut de Carcer Càrcer, Valencia, Spain
  • Centre de Salut de Pobla Llarga La Pobla Llarga, Valencia, Spain
  • Hospital General de Onteniente Ontinyent, Valencia, Spain
View Trial Details
Completed

VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma

NCT04151615

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Soonchunhyang University Bucheon hospital Bucheon-si, South Korea
  • Inje university Haeundae Paik Hospital Busan, South Korea
  • Kosin University Gospel hospital Busan, South Korea
  • Pusan national University Hospital Busan, South Korea
View all 24 locations
View Trial Details
Completed

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma

NCT03944057

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Beijing Chao-Yang Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Guangdong Provincial Peoples Hospital Guangzhou, Guangdong, China
  • Nanfang Hospital Guangzhou, Guangdong, China
View all 17 locations
View Trial Details
Completed

A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

NCT04150289

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • American Health Network Indiana Indianapolis, Indiana, United States
  • Southern Nevada Cancer Research Foundation and Optum Cancer Care Las Vegas, Nevada, United States
  • Oncology Specialists of Charlotte Charlotte, North Carolina, United States
  • Southern Oncology Specialists Huntersville, North Carolina, United States
View Trial Details
Completed

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

NCT04136756

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +21 more
Locations
  • Western Regional Medical Center - CTCA Goodyear, Arizona, United States
  • City of Hope Duarte, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
View all 13 locations
View Trial Details
Completed

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00002878

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • University of California San Diego Cancer Center La Jolla, California, United States
  • UCSF Cancer Center and Cancer Research Institute San Francisco, California, United States
  • CCOP - Christiana Care Health Services Wilmington, Delaware, United States
  • Walter Reed Army Medical Center Washington D.C., District of Columbia, United States
View all 40 locations
View Trial Details

Related conditions